Participation of Patients With Limited English Proficiency in Gynecologic Oncology Clinical Trials.

BACKGROUND Significant disparities exist in recruitment of minorities to clinical trials, with much of the prior literature focused on race/ethnicity only. Limited English proficiency (LEP) is a known barrier in healthcare that may also drive disparities in trial enrollment. We sought to determine participation rates in gynecologic oncology trials among patients with LEP and to explore barriers to their participation. METHODS In a retrospective cohort study, electronic health record data from >2,700 patients treated over 2 years at one academic gynecologic oncology practice were abstracted and the primary exposure of having LEP was identified. The primary outcome was enrollment in a clinical trial. Demographic, financial, clinical, and healthcare access-related covariates were also abstracted and considered as potential confounders in a multivariable logistic regression model. Age, race, ethnicity, and insurance status were further examined for evidence of effect modification. In addition, a survey was administered to all gynecologic oncology research staff and gynecologic oncology providers (n=25) to assess barriers to research participation among patients with LEP. RESULTS Clinical trial enrollment was 7.5% among fluent English speakers and 2.2% among patients with LEP (risk ratio, 0.29; 95% CI, 0.11-0.78; P=.007), and remained significantly lower in patients with LEP after adjusting for the identified confounders of Hispanic ethnicity and insurance payer (odds ratio, 0.34; 95% CI, 0.12-0.97; P=.043). There was a trend toward race and LEP interaction: Asian patients were equally likely to participate in research regardless of language fluency, whereas White and Black patients with LEP were less likely to participate than non-LEP patients in both groups (P=.07). Providers reported that the most significant barriers to enrollment of patients with LEP in research were unavailability of translated consent forms and increased time needed to enroll patients. CONCLUSIONS Patients with LEP were 3.4 times less likely to participate in gynecologic oncology trials than fluent English speakers. De-aggregation of race, ethnicity, and language proficiency yielded important information about enrollment disparities. These findings offer avenues for future interventions to correct disparities.

[1]  B. Bierer,et al.  Evaluating the frequency of English language requirements in clinical trial eligibility criteria: A systematic analysis using ClinicalTrials.gov , 2021, PLoS medicine.

[2]  Kevin Hur,et al.  Association Between Limited English Proficiency and Healthcare Access and Utilization in California , 2021, Journal of Immigrant and Minority Health.

[3]  A. Kurian,et al.  Limited English Proficiency and Disparities in Health Care Engagement Among Patients With Breast Cancer , 2021, JCO oncology practice.

[4]  K. Lapane,et al.  The Role of Limited English Proficiency and Access to Health Insurance and Health Care in the Affordable Care Act Era , 2020, Health equity.

[5]  J. Pierce,et al.  Minority participation in phase 1 gynecologic oncology clinical trials: Three decades of inequity. , 2020, Gynecologic oncology.

[6]  N. Gusani,et al.  Clinical Trial Accrual at Initial Course of Therapy for Cancer and Its Impact on Survival. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[7]  G. Tomlinson,et al.  Association Between Limited English Proficiency and Revisits and Readmissions After Hospitalization for Patients With Acute and Chronic Conditions in Toronto, Ontario, Canada. , 2019, JAMA.

[8]  T. Owonikoko,et al.  Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy. , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[9]  B. Karlan,et al.  Language as a barrier to cancer clinical trial accrual: assessing consenting team knowledge and practices for cancer clinical trial consent among low English fluency patients , 2018, Applied Cancer Research.

[10]  S. Temkin,et al.  A contemporary framework of health equity applied to gynecologic cancer care: A Society of Gynecologic Oncology evidenced-based review. , 2018, Gynecologic oncology.

[11]  A. Girgis,et al.  Lower trial participation by culturally and linguistically diverse (CALD) cancer patients is largely due to language barriers , 2018, Asia-Pacific journal of clinical oncology.

[12]  M. Leblanc,et al.  The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population , 2017, JAMA oncology.

[13]  Melissa M. Parker,et al.  Association of Patient-Physician Language Concordance and Glycemic Control for Limited–English Proficiency Latinos With Type 2 Diabetes , 2017, JAMA internal medicine.

[14]  Eun Ji Kim,et al.  Disparities in Hypertension Associated with Limited English Proficiency , 2017, Journal of General Internal Medicine.

[15]  E. Kohn,et al.  The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies. , 2016, Gynecologic oncology.

[16]  H. Lankes,et al.  Minority participation in Gynecologic Oncology Group (GOG) Studies. , 2014, Gynecologic oncology.

[17]  Diane P. Martin,et al.  Comparison of survival outcomes among cancer patients treated in and out of clinical trials. , 2014, Journal of the National Cancer Institute.

[18]  W. Al-Refaie,et al.  Does enrollment in cancer trials improve survival? , 2013, Journal of the American College of Surgeons.

[19]  N. Bjarnason Disparities in participation in cancer clinical trials. , 2004, JAMA.

[20]  Harlan M Krumholz,et al.  Participation in cancer clinical trials: race-, sex-, and age-based disparities. , 2004, JAMA.

[21]  M. Christian,et al.  How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Mansfield,et al.  Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years. , 2018, Journal of oncology practice.

[23]  A. Bleyer,et al.  The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[24]  PhD Daniel Goldberg JD The case for eliminating disparities in clinical trials , 2010, Journal of Cancer Education.

[25]  Mph Garth Graham MD,et al.  Addressing disparities in clinical trials: Culturally and linguistically appropriate standards in clinical trials (CLAS-ACT) and the EDICT backpack initiative , 2009, Journal of Cancer Education.